



ANNUAL REPORT REVIEW 2024



NHP MODEL AND TECHNOLOGY PLATFORM



The one-of-a-kind **NHP translation R&D center** enabled efficient NHP technology advancement in the past 2024.



PRISYS has supported **50+** global collaborators with high-quality preclinical projects of drug efficacy, safety, DMPK, biodistribution, and IND-submission.



2024 HIGHLIGHTS

RELIABLE NHP STUDIES FOR DRUG EFFICACY BY TRANSLATIONAL NHP MODELS:

- **Neurology:** Brain ischemic Stroke, Parkinson’ s disease
- **Immunology:** RA, Atopic dermatitis, Asthma, inflammation
- **Hematology:** Anemia, Bleeding, Coagulation, Thrombosis
- **Metabolic:** MASH/NASH, Obesity, T2DM
- **Ophthalmology:** Glaucoma, Retinal Pigmentosa/Neovascularization
- **Real-time MR-Navigation:** for Brain Convection Enhanced Delivery (CED)
- **Automated NHP Behavior Classification/Quantification:** for Disease manifestation, Drug efficacy, and Drug safety

IN THE PIPELINE

NOVEL NHP MODELS AND TECHNOLOGIES ARE BECOMING AVAILABLE IN 2025:

- **Neurology:** comprehensive Pain assessment, Alzheimer’ s disease
- **Immunology:** Intestinal MRI for IBD scores, DermaLab skin analysis for Psoriasis, accelerated Multiple Sclerosis development
- **Metabolic:** progressive and chronic heart/renal/liver failure
- **Respiratory:** BSL-2 pathogen exposure, IPF, COPD
- **Nasal-to-Brain (N2B) Drug Delivery Solutions in NHP**

